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Table 1. Clinical and biochemical parameters of all the 6 subjects
S No.
Primary
IST Indication
Baseline
Second month
completion
Fourth month
completion
Sixth month
completion
F/U
(mo)
Last follow-up aPLA2R (RU/ml) RTX
UP
(g/d)
Sr Alb
(g/dl)
UP
(g/d)
Sr Alb
(g/dl)
UP
(g/d)
Sr Alb
(g/dl)
UP
(g/d)
Sr Alb
(g/dl)
UP
(g/d)
Sr Alb
(g/dl) Pre-RTX Post-RTX
Additional
doses
Time
(mo)
1 cCTX/GC Relapse 8.98 3.10 3.88 3.10 3.60 3.20 1.03 3.60 14 0.701 3.70 73.11 4.528 02 03, 08
2 cCTX/GC Resistant 6.20 1.40 1.20 5.50 1.25 5.20 3.00 2.10 12 3.20 3.10 121.59 93.99 03 01, 04, 05
3 TAC Intolerant 2.30 1.30 2.90 3.13 2.86 3.42 1.92 4.32 15 0.29 4.32 28.87 2.00 04 04, 09, 12, 15
4 cCTX/GC Resistant 5.50 3.50 2.90 3.90 3.10 3.20 3.20 4.40 13 1.13 4.34 111.87 2.00 02 02, 06
5 cCTX/GC Resistant 31.00 1.68 16.220 1.59 3.80 1.98 19.60 1.83 10 8.80 3.50 27.13 79.76 02 01, 04
6 cCTX/GCa Resistant 18.41 1.60 15.03 1.30 9.58 2.63 8.00 2.00 14 3.13 3.30 59.89 56.79 03 02, 05, 06
Mean time to CD19 repletion was 2.17  1.17 (range 1–4) mo and all the subjects received further therapy (median doses 2.5, range 2–4).
aPLA2R, m-type phospholipase A2 receptor antibody; cCTX/GC, cyclical cyclophosphamide and steroids; F/U, follow-up; IST, immunosuppressive therapy; RTX, rituximab; Sr Alb, serum
albumin; TAC, tacrolimus; UP, urine protein.
aPatient developed upper respiratory tract infection, which was successfully managed with oral antibiotics.
5. Shenoy P, Bavaliya M. Efﬁcacy of very low dose (100 mg) rit-
uximab in active rheumatoid arthritis despite combination
DMARD—single center, prospective, observational study
[abstract]. Arthritis Rheumatol. 2015;67(suppl 10)
6. Cravedi P, Ruggenenti P, Sghirlanzoni MC, Remuzzi G.
Titrating rituximab to circulating B cells to optimize lympho-
cytolytic therapy in idiopathic membranous nephropathy. Clin
J Am Soc Nephrol. 2007;2:932–937.
7. Ramachandran R, Kumar V, Kumar A, et al. PLA2R antibodies,
glomerular PLA2R deposits and variations in PLA2R1 and HLA-
DQA1 genes in primary membranous nephropathy in South
Asians. Nephrol Dial Transplant. 2016;31:1486–1493.
RESEARCH LETTERSto <20 RU/ml, whereas none of the nonresponders
achieved similar titer. Our results support the incor-
poration of aPLA2R monitoring in the management of
difﬁcult to treat PMN.
To conclude, in cost-restrained setting, low-dose
RTX targeting CD19 depletion can be used in the
management of PMN refractory to standard immuno-
suppressive therapies with the acceptable side effect
proﬁle.
Raja Ramachandran1, Ashok K. Yadav1,
Vinod Kumar1, Krishan L. Gupta1 and
Harbir S. Kohli1
1Department of Nephrology, PGIMER, Chandigarh, India
Correspondence: Harbir Singh Kohli, Department of Nephrology,
Post Graduate Institute of Medical Education and Research, Sector
12, Chandigarh 160012, India. E-mail: kohlihs2009@gmail.comDISCLOSURE
All the authors declared no competing interests.
ACKNOWLEDGMENTS
ELISA for aPLA2R was performed from the scientiﬁc grants
received by Dr. Raja Ramachandran from Indian Society of
Nephrology.
REFERENCES
1. Ruggenenti P, Cravedi P, Chianca A, et al. Rituximab in idio-
pathic membranous nephropathy. J Am Soc Nephrol. 2012;23:
1416–1425.
2. Dahan K, Debiec H, Plaisier E, et al.; GEMRITUX Study Group
Rituximab for severe membranous nephropathy: a 6-month trial
with extended follow-up [e-pubaheadofprint].JAmSocNephrol.
pii: ASN.2016040449. Accessed October 13, 2016.
3. Nakao T, Ushigome H, Kawai K, et al. Evaluation of rituximab
dosage for ABO-incompatible living-donor kidney trans-
plantation. Transplant Proc. 2015;47:644–648.
4. KDIGO Clinical Practice Guideline for Glomerulonephritis.
Chapter 7: Idiopathic membranous nephropathy. Kidney Int
Suppl. 2012;2:186–197.
90ª 2016 International Society of Nephrology. Published by
Elsevier Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
Kidney Int Rep (2017) 2, 89–90; http://dx.doi.org/10.1016/
j.ekir.2016.08.019
Received 20 August 2016; revised 27 August 2016; accepted
29 August 2016; published online 6 September 2016How Well Does Serum
Albumin Correlate With
Dietary Protein Intake in
Dialysis Patients?
To the Editor: Serum albumin is a useful screening
tool for recognizing protein energy wasting (PEW) in
dialysis patients. However, there are many nonnutri-
tional conditions that are far more important de-
terminants of serum albumin levels than a patient’s
nutritional state.1,2 Nevertheless, we have observed
that it is not unusual for caregivers to make a reﬂex
connection between serum albumin and dietary protein
intake and to act on an unfounded belief that proteinKidney International Reports (2017) 2, 89–93
RESEARCH LETTERSintake is problematic when serum albumin levels are
low or declining. This may be done in the absence of
other evidence of PEW or without further nutritional
assessment.
The recognized limitations in serum albumin as a
marker for dietary protein intake deserve further
emphasis.3 We therefore examined the correlation
between serum albumin levels and dietary protein
intake (estimated by the normalized protein equivalent
of nitrogen appearance [nPNA]) in a large group of
end-stage renal disease (ESRD) patients on chronic
peritoneal dialysis (PD). We did so with the expectation
that the correlation would be poor, given the known
determinants of albumin levels. Nevertheless, we pro-
ceeded because of the ready availability of accurate
nPNA data in PD patients, the surprising absence of
prior documentation of this albumin–nPNA relation-
ship and the value of reemphasizing it.
METHODS
Medical records at the Dialysis Clinic, Inc. PD unit in
North Brunswick, NJ from 1 January 2010 to 1 January
2015 were reviewed. A total of 104 patients were
identiﬁed who had at least two 24-hour dialysate and
urine collections for urea kinetic modeling and a serum
albumin level measured on same day as the modeling.
All patients were treated with continuous cyclic PD.
All laboratory measurements were performed by
Spectra Laboratories (Rockleigh, NJ). Over- and
undercollections of urine were avoided by verbal and
written instructions on proper collection techniques.
Data from patients who had peritonitis within 8 weeks
prior to testing were excluded. Demographic and
clinical data were collected, including age, race,
gender, time of initiation of dialysis, and cause of
ESRD. Serum albumin levels were measured using the
bromocresol green method.4 The PNA was determined
from the total dialysate and urine urea content using
the Randerson II formula5:
PNA ðg=kg=dayÞ ¼ ½10:76 ð0:01
 urea generation rate
þ 1:46Þ=weight
The urea generation rate was calculated from the
urea content of the 24-hour urine and spent dialysate
collections.
All calculated PNA values were normalized (n) to
ideal weight:
nPNA ¼ ½PNAðg=dÞ=ðurea distribution volume=0:58Þ
Notably, we made no attempt to collect data on
the many variables that might alter the relationshipKidney International Reports (2017) 2, 89–93between albumin and dietary protein. The only
exception to this was our exclusion of patients with
recent peritonitis. We did this because, in our experi-
ence, we believe that clinicians are quite cognizant that
this condition will lower albumin levels and are un-
likely to draw conclusions regarding protein intake
from the results.
Statistical Analysis
Standard descriptive statistics were used for data
analysis. Mean values were calculated for the mul-
tiple nPNA and serum albumin levels for individual
patients, and results are expressed as mean  SD.
Pearson correlation and regression analysis were
used to assess the relationship between serum
albumin and nPNA levels. A 2-sided P value of less
than 0.05 was considered statistically signiﬁcant.
All statistical analyses were performed by using
Microsoft Excel 2007 (Microsoft Corp., Redmond,
WA).
RESULTS
A total of 672 nPNA and serum albumin pairs in 104
patients were analyzed (mean, 6 values per patient;
range, 222 values). Of the 104 patients, 62 were male
(60%), with a mean age of 62 years (range, 2193
years). The major causes of ESRD were diabetes (34%)
and hypertension (20%). Patients’ self-reported race
was predominately white (51%, 20% black, 10%
Asian, and 7% Hispanic).
The relationship observed between serum albumin
and nPNA is shown in Figure 1. The correlation coef-
ﬁcient was low at 0.42 (P < 0.001), with an r2 value of
0.177, indicating that only 18% of the variation in
serum albumin was accounted for by variations in the
level of nPNA.
The majority (91%) of the patients had serum
albumin levels $3 g/dl. Those with albumin levels of
3 to 3.4 g/dl had an average nPNA of 0.93 g/kg/d,
whereas those with albumin levels of 3.5–3.9 g/dl had
a mean nPNA of 0.99 g/kg/d (Table 1). Thus, in this
range of serum albumin, average nPNA declined
by about 0.01 g/kg/d for a decline of 0.1 g/dl in
albumin, or <1 g of dietary protein for a 70-kg
patient. The correlation coefﬁcient between nPNA
and serum albumin for these patients was 0.30, with
the level of nPNA accounting for only 9% of the
variation in serum albumin. However, a serum
albumin <3 g/dl was associated with a substantially
depressed nPNA.
DISCUSSION
Dietary protein intake is clearly a signiﬁcant factor in
determining serum albumin, but its importance is91
Figure 1. Relationship of normalized protein equivalent of nitrogen
appearance (nPNA) with serum albumin, with regression line and
equations. r, correlation coefﬁcient; R2, square of correlation coef-
ficient; x, albumin; y, nPNA.
RESEARCH LETTERSsometimes overstated. Residual albuminuria and
inﬂammation are much more important determinants of
serum albumin levels.1,3 When used as part of a
broader nutritional screening approach, serum albumin
is valuable. However, it is not unusual for caregivers to
equate low levels of this serum protein (albumin) to low
levels of dietary protein. This, together with the ready
availability of albumin levels, probably accounts, at
least in part, for the widespread use of serum albumin
as a nutritional marker in dialysis patients. Unfortu-
nately, when more thorough evaluations are not per-
formed, serum albumin may be perceived as the
determinant of success or failure of nutritional
interventions.
Serum albumin levels have long been recognized as
very strong predictors of outcomes in dialysis
patients.6 Furthermore, nutritional supplements may
well be beneﬁcial in patients with low serum albumin
levels and may improve their outcomes.7 However,
the basis for such improvement should not be
ascribed to correction of inadequate protein intake,
given the almost negligible relationship of albumin
levels to protein intake, at least for patients with
levels $3 g/dl.
Although nPNA determined from 24-hour urea
excretion is considered an accurate means of esti-
mating protein intake, there are some points to
consider that preclude complete conﬁdence in it. It is
based on the assumption that patients are in theTable 1. Serum albumin ranges and nPNA levels
Serum albumin (g/dl) 2.5–2.9  0.16 3–3.4 
Subjects (n) 7 30
nPNA (g/kg/d) 0.75  0.11 0.93 
nPNA, normalized protein equivalent of nitrogen appearance.
92steady state with respect to nitrogen balance. If they
are catabolic (as with an infection or high-dose ste-
roids), urea generation will suggest a protein intake
that is greater than the actual value. However, this is
much more likely to be a clinically important issue in
patients in settings other than the outpatients used in
this study.
The back calculation from urea to protein assumes
a conversion factor of 6.25 based on the Kjeldahl
nitrogen analysis. Although it is almost universally
applied, it has nevertheless been questioned.8 How-
ever, an incorrect conversion factor would only shift
the ureanPNA curve, not alter our observation of its
low R value.
Serum albumin also changes very slowly in
response to diet and other inﬂuences as a result of its
long (20-day) half-life. A poor correlation between
serum albumin and nPNA could reﬂect, at least in
part, the snapshot that nPNA reﬂects—analogous to a
blood glucose compared to an HbA1c level. However,
our analysis used an average of 6 pairs of nPNA–al-
bumin results per patient, thereby abrogating much
of this consideration.
The use of nPNA in a peritoneal dialysis setting is
much less problematic than its use in hemodialysis.
The problems in the latter include its nonsteady state,
the rebound in blood urea nitrogen after dialysis, the
typical absence of urine collections, and the calculation
of urea generation from changes in the blood urea
nitrogen and estimates of urea distribution volume.
The nonsteady state issue also applies to a much lesser
extent in our population, as CCPD provides more
dialysis in the nocturnal period. This will generally
make the daytime values that we obtained slightly
different from the time-averaged blood urea nitrogen;
values were usually measured in the morning when the
blood urea nitrogen would be less than the time-
averaged urea, leading to an overestimate of nPNA
and dietary protein. However, this effect is likely to be
minor.
This report of the poor correlation between nPNA
and serum albumin is not a ground-breaking observa-
tion and is fully consistent with a large body of other
data in this area. However, it serves to highlight a
recognized concern in the interpretation of serum
albumin levels and adds a quantitative dimension to
the relationship between dietary protein and serum0.15 3.5–3.9  0.13 4–4.4  0.17
50 15
0.23 0.99  0.22 1.1  0.26
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RESEARCH LETTERSalbumin. Clearly, serum albumin is not a surrogate
for dietary protein intake, nor can it serve as an in-
dependent measure suitable for assessing a patient’s
nutritional state.
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